Your search for dapagliflozin returned 105 results

A total of 70,177,200 individuals were included in the final analysis; 234,840 had CRC and 69,942,360 had no CRC.

Dapagliflozin is sodium-glucose cotransporter 2 inhibitor.

Latest findings are from a post hoc meta-analysis of pooled data from the DAPA-HF and DELIVER trials.

Despite a warning from the FDA Adverse Event Reporting System, studies have found that SGLT2 inhibitor use is not associated with an increased risk of AKI.

Dapagliflozin, metformin HCl ext-rel; 2.5mg/1000mg, 5mg/500mg, 5mg/1000mg, 10mg/500mg, 10mg/1000mg; tabs.

The summary below gives an overview of important additions and changes MPR has made to its drug database through the end of January. The chart below provides highlights of key monograph updates made this month (not an inclusive list). Click on the name of the drugs to view the full monographs on eMPR.com. Key: D=Dosing,…

Reduction seen in rate of admissions due to cardiac disorders, renal and urinary disorders, metabolism and nutrition disorders, neoplasms

Primary end point similarly reduced for men and women with dapagliflozin; no differences in secondary outcomes, safety events

Dapagliflozin 5mg, 10mg; tabs.

The findings were consistent across key subgroups examined (eg, LVEF<60%, diabetes)